GlassScriptPhysician profile
Amy J Hennessy
NPI 1629403134
$10,296.65
in general payments reported to CMS, 2019-2025
27 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,371 · 2022: $1,970 · 2023: $2,485 · 2024: $2,261 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,494 · Education: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,494.21 |
| Education | $460.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,130.94 | 2021-2025 | |
| Janssen Biotech, INC. | $1,222.35 | 2021-2025 | Tremfya, Simponi, Stelara |
| E.R. Squibb & Sons, L.L.C. | $966.40 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $930.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $712.79 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $706.17 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $682.41 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $681.36 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $493.92 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $339.73 | 2021-2024 | Adbry |
| Galderma Laboratories, L.P. | $302.69 | 2021-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $230.79 | 2023-2024 | Vtama |
| Pfizer INC. | $200.21 | 2021-2025 | |
| Incyte Corporation | $106.86 | 2022-2024 | Opzelura |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $78.25 | 2022-2025 | Klisyri, Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.23 | 2023-2025 | Spevigo, Cyltezo |
| Amgen INC. | $71.69 | 2022-2025 | Otezla, Otezla |
| Epi Health, LLC | $56.46 | 2021-2022 | |
| Organon LLC | $47.47 | 2025 | Vtama |
| Biofrontera INC. | $42.38 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.47 | 2021 | |
| Verrica Pharmaceuticals INC. | $35.02 | 2024-2025 | Ycanth |
| Vyne Pharmaceuticals INC. | $20.86 | 2021 | |
| Arcutis Biotherapeutics, INC. | $19.95 | 2025 | Zoryve |
| Dermira, INC. | $15.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hennessy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.